

BIBLIOGRAPHY

- Acocella, G. and Conti, R. 1980. Interaction of rifampicin with other drugs. *Tubercel.* 61: 171-177.
- Abraham, M.A., Thomas, P.P., John, G.T., *et al.* 2003. Efficacy and safety of low-dose ketoconazole (50 mg) to reduce the cost of cyclosporine in renal allograft recipients. *Transplantation Proceedings.* 35: 215-216.
- Adjepon-Yamoah, K.K., Edwards, G., Breckenridge, A.M., *et al.* 1982. The effect of renal disease on the pharmacokinetics of diethylcarbamazine in man. *Br. J. Clin. Pharmacol.* 13: 829-834.
- AMA. 1991. Department of Drugs: Drug Evaluations Subscription. *American Medical Association*, Chicago, IL.
- Annual Report of Filariasis Division. 2002. Department of Communicable Disease Control, Ministry of Public Health: 79-82.
- Anon. 1992. Drug of treatment of fungal infection. *Med. Lett. Drugs Ther.* 34: 14-16.
- Anon. 1993. Report of dangerous cardiac arrhythmias prompt new contra-indications for the drug hismanal. *FDA Med. Bull.* 23(1): 2-3.
- Annas, A., Carlström, K., Alov'an, G., and AL-Shurbaji, A. 2003. The effect of ketoconazole and diltiazem on oestrogen metabolism in postmenopausal women after single dose oestradiol treatment. *Br. J. Clin. Pharmacol.* 56: 334-336.

- van Aubel, R.A.M.H., Masereeuw, R., and Russel, F.G.M. 2000. Molecular pharmacology of renal organic anion transporters. *Am. J. Physiol. Renal. Physiol.* 279: F216-F232.
- Awadzi, K., Adjepon-Yamoah, K.K., Edwards, G., Orme, M. L'E., Breckenridge, A.M., and Gilles, H.M. 1986. The effect of moderate urine alkalinisation on low dose DEC therapy in patients with onchocerciasis. *Br. J. Clin. Pharmacol.* 21: 669-676.
- Backman, J.T., and Jauregui, L. 1993. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status *in vivo*. *Xenobiotica.* 23: 307-315.
- Backman, J.T., Luurila, H., Neuvonen, M., and Neuvonen, P.J. 2005. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. *Clin. Pharmacol. Ther.* 78(2): 154-167.
- Backman, J.T., Olkkola, K.T., and Neuvonen, P.J. 1996. Rifampicin drastically reduces plasma concentrations and effects of oral midazolam. *Clin. Pharmacol. Ther.* 59: 7-13.
- Balbi, C., D'Ajello, M., and Balbi, G.C. 1986. Treatment with ketoconazole in diabetic patients with vaginal candidiasis. *Drugs Exp. Clin. Res.* 12: 413-414.
- Baldwin, S.J., Bloomer, J.C., Smith, G.I., Ayrton, A.D., and Clarke, S.E. 1995. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. *Xenobiotica.* 25: 261-271.
- Barbarash, R.A. 1985. Verapamil-rifampicin interaction. *Drug Intell. Clin. Pharmacol.* 19: 559-560.

- Barditch-Crovo, P., Trapnell, C.B., Ette, E., Zacur, H.A., Coresh, J., Rocco, L.E., Hendrix, C.W., and Flexner, C. 1999. The effects of rifampicin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. *Clin. Pharmacol. Ther.* 65: 428-438.
- Benet, L.Z., Kroetz, D.L., and Sheiner, L.B. 1996. Biotransformation of drugs, in Hardman J.G., Limbird L.L., Molinoff P.B., *et al.* (eds). *Goodman and Gilman's : The Pharmacological Basis of Therapeutics*. (9th ed.), New York, McGraw-Hill. pp. 3-28.
- Bolla, S., Boinpally, R.R., Poondru, S., Devaraj, R., and Jasti, B.R. 2002. Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. *J. Clin. Pharmacol.* 42: 327-331.
- Bolton, A.E., Peng, B., Hubert, M., Krebs-Brown, A., Capdeville, R., Keller, U., and Seiberling, M. 2004. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. *Cancer Chemother. Pharmacol.* 53: 102-106.
- Boman, G. 1974. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicic acid and isoniazid. *Eur. J. Clin. Pharmacol.* 7: 215-225.
- Boman, G., Hanngren, A., and Malmberg, A.S. 1971. Drug interaction: decreased serum concentrations of rifampicin when given with P.A.S. *Lancet.* 17: 800.
- Borin, M.T., Chambers, J.H., Carel, B.J., Gagnon, S., and Freimuth, W.W. 1997. Pharmacokinetic study of the interaction between rifampicin and delavirdine mesylate. *Clin. Pharmacol. Ther.* 61: 544-553.

- Boyd, M.A., Zhang, X., Dorr, A., Ruxrungthan, K., Kolis, S., Nieforth, K., Kinchebw, T., Buss, N., and Patel, I.H. 2003. Lack of enzyme-inducing effect of rifmapicin on the pharmacokinetics of enfuvirtide. *J. Clin. Pharmacol.* 43: 1382-1391.
- Brass, C., Galgiani, J.N., Blaschke, T.F., *et al.* 1982. Disposition of ketoconazole, an oral antifungal, in humans. *Antimicrob. Agents Chemother.* 21: 151-158.
- Brown, M.W., Maldonado, A.L., Meredith, C.G., *et al.* 1985. Effect of ketoconazole on hepatic oxidative drug metabolism. *Clin. Pharmacol. Ther.* 37: 290-297.
- Burger, D.M., Meenhorst, P.L., Koks, C.H.W., and Beijnen, J.H. 1993. Pharmacokinetic interaction between rifampicin and zidovudine. *Antimicrob. Agents Chemother.* 37: 1426-1431.
- Bussey, H.I. 1982. The influence of quinidine and other agents on digitalis glycosides. *Am. Heart J.* 104: 284-302.
- Bussey, H.I., Merrit, G.J., and Hill E.G. 1984. The influence of rifampin on quinidine and digoxin. *Arch. Intern Med.* 144: 1021-1023.
- Carlson, J.A., Mann, H.J., and Canafax, D.M. 1983. Effect of pH on disintegration and dissolution of ketoconazole tablets. *Am. J. Hosp. Pharm.* 40: 1334-1336.
- Cashman, J.R. 2004. The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. *DDT.* 9(13): 574-581.
- Cashman, J.R., and Zhang, J. 2002. Interindividual differences of human flavin-containing monooxygenase 3 : Genetic polymorphisms and functional variation. *Drug Metab. Dispos.* 30(10): 1043-1052.

- CDC. 1993. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. pp. 1-17.
- Chamber, H.F. 2001. Antimicrobial Agents. Goodman & Gilman's: The pharmacological Basis of Therapeutics (10th ed.). New York: *McGraw-Hill*. pp. 1301-1304.
- Chambers, H.F., and Jawetz E. 1998. Antimycobacterial drugs. In B.G. Katzung (ed.), Basic and Clinical Pharmacology (7th ed.). New Jersey: Prentice-Hall International Inc. pp. 770-779
- Chenhsu, R.Y., Loong, C.C., Chou, M.H., Lin, M.F., and Yang, W.C. 2000. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. *The Annals of Pharmacotherapy*. 34: 27-31.
- Choo, E.F., Leake, B., Wandel, C., *et al.* 2000. Pharmacological inhibition of P-glycoprotein transports enhances the distribution of HIV-1 protease inhibitors into brain and testis. *Drug. Metab. Dispos.* 28: 655-660.
- Ciarimboli, G., and Schlatter, E. 2005. Regulation of organic cation transport. *Eur. J. Physiol.* 449: 423-441.
- Cleary, J.D., Taylor, J.W., and Chapman, S.W. 1992. Itraconazole in antifungal therapy. *The Annals of Pharmacotherapy*. 26: 502-511.
- Combalbert, J., Fabre, I., Fabre, G., Dalet, I., and Derancourt, J. 1989. Metabolism of cyclosporin A: I.V. purification and identification of the rifampicin-inducible human liver cytochrome P450 (Cyclosporin A oxidase) as a product of P-450 III a gene subfamily. *Drug Metab. Dispos.* 17: 197-207.
- Como, J.A., and Dismukes, W.E. 1994. Oral azole drugs as systemic antifungal therapy. *New Eng. J. Med.* 330: 263-272.

- Correia, M.A. 1998. Drug biotransformation. In B.G. Katzung (ed.), Basic and Clinical Pharmacology. 7th ed. New Jersey: *PrenticeHall*. pp. 50-61
- Córdoba-Díaz, D., Córdoba-Díaz, M., Awad, S., and Córdoba-Borrego, M. 2001. Effect of pharmacotechnical design on *in vitro* interaction of ketoconazole tablet with non-systemic antacid. *Int. J. Pharm.* 226: 61-68.
- Cuce, L.C., Wroclawski, E.L., and Sampaio, S.A.P. 1980. Treatment of paracoccidioidomycosis, candidosis, lobomycosis, and mycetoma with non-systemic antacid. *Int. J. Pharm.* 226: 61-68.
- Cvetkovic, M., Leake, B., Fromm, M.F., Wilkinson, G.R., and Kim, R.B. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. *Drug Metab. Dispos.* 27: 866–871.
- Daneshmend, T.K. 1990. Diseases and drugs but not food decrease ketoconazole bioavailability. *Br J Clin Pharmacol.* 29: 783-784.
- Daneshmend, T.K., Warnock, D.W., Ene, M.D., *et al.* 1983. Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetic in man. *Antimicrob. Agents Chemother.* 226: 61-68.
- Daneshmend, T.K., Mason, A.R., Warnock, D.W., *et al.* 1984. Influence of food on the pharmacokinetics of ketoconazole. *Antimicrob Agents Chemother.* 25(1): 1-3.
- Daneshmend, T.K., Mason, A.R., Warnock, D.W., *et al.* 1986. Influence of formulation on ketoconazole pharmacokinetics in man : comparison of standard tablet versus capsule containing citric acid. *J. Anti. Chem.* 18: 289-291.

- Daneshmend, T.K., Warnock, D.W., Ene, M.D., *et al.* 1984. Influence of food on the pharmacokinetics of ketoconazole. *Antimicrob. Agents Chemother.* 25(1): 1-3.
- Dilger, K., Hofmann, U., and Klotz, U. 2000. Enzyme induction on the elderly: effect of rifampicin on the pharmacokinetics and pharmacodynamics of propafenone. *Clin Pharmacol Ther.* 67: 512-520.
- Doble, N., Shaw, R., Rowland-Hill, C., Lush, M., Warnock, D.W., and Keal, E.E. 1988. Pharmacokinetic study of interaction between rifampicin and ketoconazole. *J. Antimicrob. Chemother.* 21: 633-635.
- Dollery, C. 1999. Itraconazole, Ketoconazole, Quinine. In: *Therapeutic Drugs*. 2nd vol 2, London: *Hardout brace*. pp. 12-126.
- Dresser, M.J., Leabman, M.K., and Giacomini, K.M. 2001. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. *J. Pharm. Sci.* 90: 397-421.
- Droste, J.A.H., Verwelj-van Wissen, C.P.W.G.M., Kearney, B.P., Buffels, R., vanHorsen, P.J., Hekster, Y.A., and Burger, D.M. 2005. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. *Antimicrob. Agents Chemother.* 49(2): 680-684.
- Ebert, U., Thong, N.Q., Oertei, R., and Kirch, W. 2000. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. *Eur. J. Clin. Pharmacol.* 56: 299-304.
- Edwards, G., Breckenridge, A.M., Adgepon-Yamoah, K.K., Ome, M.L., Ward, S.A. 1981. The effect of variations in urinary pH on the pharmacokinetics of diethylcarbamazine. *Br.J. Clin. Pharmacol.* 12: 807-812.

- Edwards, G., and Brckenridge, A.M. 1988. Clinical pharmacokinetics of anthelmintic drugs. *Clin. Pharmacokinet.* 15: 67-93.
- Eller, M.G., and Okerholm, R.A. 1991. Pharmacokinetic interaction between terfenadine and ketoconazole (abstract). *Clin. Pharmacol. Ther.* 49: 130.
- Engel, F.K., ten Tije, A.J., Baker, S.D., Lee, C.K.K., Loos, W.J., Vulto, A.G., Verweij, J., and Sparreboom, A. 2004. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. *Clin. Pharmacol. Ther.* 75(5): 448-454.
- Fabris, A., Pellanda, M.V., Gardin, C., *et al.* 1993. Pharmacokinetics of antifungal agents. *Peritoneal Dialysis International.* 13(suppl 2): S380-382.
- Fauci, A.S., Macher, A.M., Lango, D.L., *et al.* 1984. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. *Ann. Intern. Med.* 100: 92-106.
- FDA Thailand. 2004. Guideline of the recommendation for bioequivalence study. pp. 1-9
- Finch, C.F., Chrisman, C.R., Baciewicz, A.M., Self, T.H. 2002. Rifampin and rifabutin drug interactions. *Arch. Intern. Med.* 162: 985-92.
- Fleisaker, J.C., Pearson, P.G., Wienkers, L.C., *et al.* 1996. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. *J. Pharmacol. Exp. Ther.* 227(2): 991-998.
- Fromm, M.F., Busse, D., Kroemer, H.K., and Eichelbaum, M. 1996. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. *Hepatology.* 24: 796-801.

- Fromm, M.F., Dilger, K., Busse, D., Kroemer, H.K., Eichelbaum, M., Klotz, U. 1998. Gut metabolism of verapamil in older people: effect of rifampicin-mediated enzyme induction. *Br. J. Clin. Pharmacol.* 45: 247-255.
- Fromm, M.F., Eckhardt, K., Li, S., Schanzle, G., Hofmann, U., Mikus, G., and Eichelbaum, M. 1997. Loss of analgesic effect of morphine due to coadministration of rifampin. *Pain.* 72: 261-267.
- Gallicano, K.D., Sahai, J., Shukla, V.K., Seguin, I., Pakuts, A., Kwok, D., Foster, B.C., and Cameron, D.W. 1999. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. *Br. J. Clin. Pharmacol.* 48: 168-179.
- Garfield, J.W., Kreek, M.J., and Giush, L.M. 1975. Rifampin-methadone interaction. *American Review of Respiratory Diseases.* 3: 926.
- Gascoigne, E.W., Barton, G.J., Michaels, M., *et al.* 1981. The kinetics of ketoconazole in animal and man. *Clin. Res. (Review).* 1: 177-187.
- Gault, H., Langerich, L., Dawe, M., and Fine, A. 1984. Digoxin-rifampin interaction. *Clin. Pharmacol. Ther.* 35: 752-754.
- Geick, A., Eichelbaum, M., and Burk, O. 2001. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. *J. Biol. Chem.* 276(18): 14581-14587.
- Gelband, H. 1994. Diethylcarbamazine salt in the control of lymphatic filariasis. *Am. J. Trop. Med. Hyg.* 50: 655-662.
- Ghetti, P., Patrone, P., and Tosti, A. 1986. Ketoconazole in the treatment of acne in women (letter). *Arch. Dermatol.* 122: 629.

- Giacomini KM, and Sugiyama Y. Membrane transporters and drug response. 2006. Goodman & Gilman's: The pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill. pp. 41-70.
- Gillum, J.G., Sesler, J.M., Bruzzese, V.L., Israel, D.S., and Polk, R.E. 1996. Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. *Antimicrob. Agents Chemother.* 40: 1866-1869.
- Gilman, A.G., Rall, T.W., and Nies, A.S., *et al.* 1990. Goodman and Gilman's (8th ed.): The Pharmacological Basis of Therapeutics. New York: Pergamon Press,
- Ginsburg, C.M., McCracken, G.H., and Olsen, K. 1983. Pharmacology of ketoconazole suspension infants and children. *Antimicrob. Agents Chemother.* 23: 787-789.
- Gonzalez, F.J., and Idle, J.R. 1994. Pharmacogenetic phenotyping and genotyping present status and future potential. *Clin. Pharmacokinet.* 26: 59-70.
- Gonzalez, F.J., and Tukey, F.J. 2006. Drug metabolism. Goodman & Gilman's: The pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill. pp. 71-92
- Gramatte, T., and Oertel, R. 1999. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. *Clin. Pharmacol. Ther.* 66: 239-245.
- Granzotto, M., Drigo, I., Candussio, L., Rosati, A., Bartoli, F., Giraldi, T., and Decorti, G. 2004. Rifampicin and verapamil induce the expression of P-glycoprotein *in vivo* in Ehrlich ascites tumor cells. *Cancer Letters.* 205: 107-115.
- Graybill, J.R., and Drutz, D.J. 1980. Ketoconazole: A major innovation for treatment of fungal decrease. *Ann. Intern. Med.* 93: 921-923.

- Graybill, J.R., Galgiani, J.N., Jorgensen, J.H., *et al.* 1983. Ketoconazole therapy for fungal urinary tract infections. *J. Urol.* 129: 68-70.
- Greenblatt, D.J., von Moltke, L.L., Harmatz, J.S., *et al.* 1993. Alplazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. *J. Clin. Psychiatry.* 54 (suppl 10): 4-11.
- Greenblatt, D.J., von Moltke, L.L., Harmatz, J.S., *et al.* 1998. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. *Clin. Pharmacol. Ther.* 64: 661-671.
- Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.P., Richter, O.V., Zundler, J., and Kroemer, H.K. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. *J. Clin. Invest.* 104(2): 147-153.
- Guengerich, F.P., Brian, W.R., Iwasaki, M., *et al.* 1991. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 3A4. *J. Med. Chem.* 34: 1838-1844.
- Guengerich, F.P. 1988. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. *Cancer Res.* 48(11): 2946-54.
- Halbert, J.R. 1995. Structural basis of selective cytochrome P450 inhibition. *Annual Review of Pharmacology and Toxicology.* 35: 29-53.
- Hamman, M.A., Bruce, M.A., Haehner-Daniels, B.D., and Hall, S.D. 2001. The effect of rifampin administration on the disposition of fexofenadine. *Clin. Pharmacol. Ther.* 69: 114-121.
- Hawkin, S.S., Greony, D.W., and Alford, R.H. 1981. Progressive disseminated histoplasmosis: favorable response to ketoconazole. *Ann. Intern. Med.* 95: 446-449.

- Hawking, F. 1979. Diethylcarbamazine and new compounds for the treatment of filariasis. *Adv. Pharmacol. Chemother.* 16: 129-194.
- Hebert, M.F., Roberts, J.P., Prueksaritanont, T., and Benet, L.Z. 1992. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. *Clin. Pharmacol. Ther.* 52: 453-457.
- Hebert, M.F., Fisher, R.M., Marsh, C.L., Dressler, D., and Bekersky, I. 1999. Effects of rifampicin on tacrolimus pharmacokinetics in healthy volunteers. *J. Clin. Pharmacol.* 39: 91-96.
- Heel, R.C., Brogden, R.N., Carmine, A., *et al.* 1982. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. *Drugs.* 231-36.
- Heimark, L.D., Gibaldi, M., Trager, W.F., O' Reilly, R.A., and Goubart, D.A. 1987. The mechanisms of warfarin-rifampicin drug interaction in human. *Clin. Pharmacol. Ther.* 42: 388-394.
- Heinig, R., Adelman, H.F., and Ahr, G. 1999. The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine. *Eur. J. Clin. Pharmacol.* 55: 57-60.
- Herman, B.D., Fleishaker, J.C., and Brow, M.T. 1999. Ketoconazole inhibits the clearance of the enantiomers of antidepressant reboxetine in humans. *Clin. Pharmacol. Ther.* 66 (4): 374-379.
- Hinderling, P.H., and Hartmann 1991. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. *Ther. Drug Monit.* 13: 381-401.

- Holdiness, M.R. 1984. Clinical pharmacokinetics of the antituberculosis drugs. *Clin. Pharmacokinet.* 9: 511-544.
- Holtbecker, N., Fromm, M.F., Kroemer, H.K., Ohnhaus, E.E., and Heidemann, H. 1996. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. *Drug Metab. Dispos.* 24(10): 1121-3.
- Honing, P.K., Wortham, D.C., Hill, R., *et al.* 1993. Itraconazole affects single dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. *J. Clin. Pharmacol.* 33: 1201-1206.
- Hoogerwerf, W.A., and Pasricha, P.J. 2006. Pharmacotherapy and gastric acidity peptic ulcers, and gastroesophageal reflux disease. Goodman & Gilman's: The pharmacological Basis of Therapeutics (11th ed.); pp.967-981. New York: McGraw-Hill.
- Hoppu, K., Tapanainen, P., Tikanoja, T., *et al.* 1991. Accidental astemizole overdose in young children. *Lancet.* 338: 538-539.
- Hunter, J., Jepson, M.A., Tsuruo, T., Simmons, N.L., and Hirst, B.H. 1993. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. *J. Biol. Chem.* 268: 14991-14997.
- Ilondu, N., Orisakwe, O.E., Ofoefule, S., Afonne, O.J., Obi, E., Chilaka, K.C., and Orish, C. 2000. Pharmacokinetics of diethylcarbamazine: prediction by concentration in saliva. *Biol. Pharm. Bull.* 23(4): 443-445.
- Jaroszewski, J.W., Berenstein, D., Slok, F.A., Simonsen, P.E., Agger, M.K. 1996. Determination of diethylcarbamazine, an antifilarial drug, in human urine by ¹H-NMR spectroscopy. *J. Pharm. Biomed. Anal.* 14: 543-549.

- Jaruratanasirikul, S., and Sriwiriyan, S. 1998. Effects of rifampicin on the pharmacokinetics of itraconazole in normal normal volunteers and AIDS patients. *Eur. J. Clin. Pharmacol.* 54: 155-158.
- Josefsson, M., Zackrisson, A.L., and Ahlner, J. 1996. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. *Eur. J. Clin. Pharmacol.* 51: 189-193.
- Karlsson, J., Kuo, S.M., Ziemniak, J., and Artursson, P. 1993. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. *Br. J. Pharmacol.* 110(3): 1009-16.
- Kekuda, R., Prasad, P.D., Wu, X., *et al.* 1998. Cloning and functional characterization of a potential-sensitive polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. *J. Biol. Chem.* 273: 15971-15979.
- Kelly, H., Kelly, H.W., Couch, R.C., Davis, R.L., Cushing, A.H., and Knon, R. 1988. Interactions of chloramphenicol and rifampicin. *J. Pediatr.* 112: 817-820.
- Keogh, A., Spratt, P., McCosker, C., *et al.* 1995. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. *N. Engl. J. Med.* 333: 628-633.
- Khaliq, Y., Gallicano, K., Venance, S., *et al.* 2000. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patient infected with human immunodeficiency virus. *Clin. Pharmacol. Ther.* 68: 637-646.
- Khosla, S., Wolfson, J.S., Demerjian, Z., *et al.* 1989. Adrenal crisis in the setting of high-dose ketoconazole therapy. *Arch. Intern. Med.* 149: 802-804.

- Kim, R.B., Fromm, M.F., Wandel, C., *et al.* 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitor. *J. Clin. Invest.* 101: 289-294.
- Klion, A.D., Horton, J., Nutman, T.B. 1999. Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. *Clin. Infect. Dis.* 29(3): 680-2.
- Koch, H. 1983. Keoconazole. *Pharm. Int.* 4: 151-152.
- Kosten, T.R., Oliveto, A., Sevarino, K.A., *et al.* 2002. Ketoconazole increases cocaine and opioid use in methadone maintained patients. *Drug and Alcohol Dependence.* 66: 173-180.
- Kovacs, G.T., Westcott, M., and Rusden, J. 1990. A prospective study to assess the efficacy of ketoconazole in the treatment of recurrent vaginal candidiasis. *Med. J. Aust.* 153: 328-330.
- Kovarik J.M., Beyer D., Bizot M.N., Jiang Q., Shenouda M., and Schmouder R.L. 2005. Blood concentrations of everolimus are markedly increased by ketoconazole. *J. Clin. Pharmacol.* 45: 514-518.
- Krishnaiah, Y.S.R., Satyanarayana, S., and Visweswaram, D. 1993. Drug interaction of tolbutamide with ketoconazole in diabetic rabbits. *Indian J. Pharmacol.* 25(3): 146-148.
- Krueger, S.K., and Williams D.E. 2005. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. *Pharmacol. Ther.* 106: 357-387.

- Kuroha, M., Kuze, Y., Shimoda, M., and Kokue, E. 2002. In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. *Am. J. Vet. Res.* 63(6): 900-5.
- Kuroha, M., Shirai, Y., Shimoda, M. 2004. Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs. *J Vet Pharmacol Ther.* 27(5): 355-9.
- Kyrklund, C., Backman, J.T., Kivisto, K.T., Neuvonen, M., Laitila, J., and Neuvonen, P.J. 2000. Rifampicin greatly reduces plasma simvastatin and simvastatin acid concentrations. *Clin. Pharmacol. Ther.* 68: 592-597.4
- Lamberg T.S., Kivisto K.T., Neuvonen P.J. 1998. Concentrations and effects of buspirone are considerably reduced by rifampicin. *Br. J. Clin. Pharmacol.* 45: 381-385.
- Lee, K.H., Shin, J.G., Chong, W.S., Kim, S., Lee, J.S., Jang, I.J., and Shin, S.G. 1993. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. *Eur. J. Clin. Pharmacol.* 45: 287-289.
- Lee, S., Casteel, D.A., and Fleckenstein, L. 1997. Specific gas chromatographic analysis of diethylcarbamazine in human plasma using solid-phase extraction. *J. Chromatogr B.*, 701: 181-185.
- Lelawongs, P., Barone, J.A., Colaizzi, J.L., Hsuan, A.T., Mechlinski, W., Legendre, R., Guarnieri, J. 1988. Effect of food and gastric acidity on absorption of orally administered ketoconazole. *Clin. Pharm.* 7(3): 228-35.
- Li, X.Q., Björkman, A., Andersson, T.B., Gustafsson L.L., and Masimirembwa, C.M. 2003. Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of *in vivo* drug hepatic clearance from *in vitro* data. *Eur. J. Clin. Pharmacol.* 59: 429-442.

- Lilja, J.J., Niemi, M., Neuvonen, P.J. 2004. Rifampicin reduces plasma concentrations of celiprolol. *Eur. J. Clin. Pharmacol.* 59: 819-824.
- Lin, J.H., and Lu, A.Y.H. 1998. Inhibition and induction of cytochrome P450 and the clinical implications. *Clin. Pharmacokinet.* 35: 361-390.
- Lin, J.H. 2003. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. *Advanced Drug Delivery Review.* 55: 53-81.
- Lippert, C., Ling, J., Brown, P., Burmaster, S., Eller, M., Cheng, L., Thompson, R., and Weir, S. 1999. Mass balance and pharmacokinetics of MDL16,455A in healthy male volunteers. *Pharm. Res.* 12: 390, abstract.
- Lucksiri A., Vuppalanchi R., Hilligoss J.K., Hamman M.A., Li L., Chien J.Y., Huang S., Hall S.D. 2005. Dose dependent inhibition of midazolam elimination by ketoconazole: Effect of CYP3A5 genotype. *Clin. Pharmacol. Ther.* 77: 35.
- Lyman, C.A., and Walsh, T.J. 1992. Systemically administered antifungal agent a review of their clinical pharmacology and therapeutic application. *Drug.* 44(1): 18-34.
- Mackenzie, C.D., and Kron, M.A. 1985. Diethylcarbamazine: a review of its action in onchocerciasis, lymphatic filariasis and inflammation. *Trop. Dis. Bull.*, 82: R1-R37.
- Magnarin, M., Morelli, M., Rosati, A., Bartoli, F., Candussio, L., Giraldi, T., and Decorti, G. 2004. Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK₁ cells. *Eur. J. Pharmacol.* 483: 19-28.
- Maksymink, A.W., Levine, H.B., and Bodey, G.P. 1982. Pharmacokinetics of ketoconazole in patients with neoplastic diseases. *Antimicrob. Agents Chemother.* 22: 43-46.

- Mandell, G.I., Douglas, R.G., and Bennett, J.E. (eds) 1990. Principles and Practice of Infectious Diseases, 3rd ed. Churchill Livingstone, New York, NY.
- Mandell, G.L., and Sandle, M.A. 1996. Antimicrobial agents : drug used in the chemotherapy of tuberculosis and leprosy. In L.S. Goodman and A.G. Gilman (eds.), *Pharmacological Basis of Therapeutics* (8th ed.). New York: McGraw-Hill. pp. 1146-1164
- Martin, R.J., Robertson, A.P., and Bjorn, H. 1997. Target sites of anthelmintics. *Parasitology*, 114(suppl): S111-S124.
- Mathews, D.R., McNutt, B., Okerholm, R., *et al.* 1991. Torades de pointes occurring in association with terfenadine use (letter). *JAMA*. 266: 2375-2376.
- Mathew, N., and Kalyanasundaram, M. 2001. High performance liquid chromatographic method for the estimation of diethylcarbamazine content in medicated salt samples. *Acta. Tropica*. 80: 97-102.
- Martinez-Jorda, R., Rodriguez-Sasiain, J.M., *et al.* 1990. Serum binding of ketoconazole in health and disease. *Int. J. Clin. Pharm. Res.* 10: 271-276.
- McDonald, L.C., Archibald, L.K., Rheapumiikankit, S., Tansuphaswadikul, S., Eampokalap, B., Nwanyanawu, O., Kazembe, P., Kobbie, H., Reller, L.B., and Jarvis, W.R. 1999. Unrecognised Mycobacterium tuberculosis bacteraemia among hospital inpatients in less developed countries. *Lancet*. 354: 1159-1163.
- McGrawth, J., and Murphy, G.M. 1991. The control of seborrhoeic dermatitis and dandruff by antipityrosporal drugs. *Drugs*. 41(2): 178-184.

- Menicol, M.W., Campbell, I.A., and Jenkins, P.A. 1995. Clinical features and management. In R. Brewis, B. Corrin, D.M. Geddes and G.J. Gibson (eds.), *Respiratory Medicine* (2nd ed.), London: Saunders Company Ltd. pp. 805-832.
- Meyer, K.C., McManus, E.J., and Maki, D.G. 1993. Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome. *N. Eng. J. Med.* 329: 1231-1236.
- Micromedex Healthcare Series. Drugdex drug evaluations: Diethylcarbamazine (online). Available: <http://cdserv.pharmacy.psu.ac.th/mdxcgi/display.exe?CTL>. (25/7/2004).
- Miller, Jr. J.R., and Fleckenstein, L. 2001. Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetics studies. *J. Pharm. Biomed. Anal.* 26: 665-674.
- Mirghani, R.A., Hellgren, U., Westerberg, P.A., Ericsson, O., Bertilsson, L., Gustafsson, L.L. 1999. The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine *in vivo*. *Clin. Pharmacol. Ther.* 66(5): 454-460.
- Mitsui, Y., Takamura, N., Fujimaki, Y., Yamaguchi, T., Kitagawa, T., and Aoki, Y. 1996. Development of a competitive enzyme-linked immunosorbent assay for diethylcarbamazine. *Trop Med Int Health*, 1(4): 528-534.
- Mobacken, H., and Moberg, S. 1986. Ketoconazole treatment of 13 patients with chronic mucocutaneous candidiasis: a prospective 3 years trial. *Dermatological.* 173: 229-236.
- von Moltke, L.L., Greenblatt, D.J., Cotreau-Bibbo, M.M., *et al.* 1994. Inhibitor of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. *Br. J. Clin. Pharmacol.* 38: 23-31.

- von Moltke, L.L., Granda, B.W., Grassi, J.M., Perloff, M.D., Vishnuvardhan, D., and Greenblatt, D.J. 2004. Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. *J. Pharmacol. Exp. Ther.* 32(8): 800-804.
- Moody, D.E., Walsh, S.L., Rollins, D.E., Neff, J.A., and Huang, W. 2004. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl- α -methadol in opioid-naïve individuals. *Clin. Pharmacol. Ther.* 76(2): 154-166.
- Mordel, A., Halkin, H., Zulty, L., Almog, S., and Zra, D. 1993. Quinidine enhances digitalis toxicity at therapeutic serum digoxin levels. *Clin. Pharmacol. Ther.* 53: 457-462.
- Moreno, S., Podzamczar, D., Blazquez, R., Iribabarren, J.A., Ferrer, E., Reparaz, J., Pena, J.M., Cabrero, E., and Usan, L. 2001. Treatment of tuberculosis in HIV-infected patients : safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampicin. *AIDS.* 15(9): 1185-1187.
- Mouelhi, M.E., Worley, D.J., Kuzmak, B., Destefno, A.J., and Thompson, G.A. 2004. Influence of ketoconazole on azimilide pharmacokinetics in healthy subjects. *Br. J. Clin. Pharmacol.* 58(6): 641-647.
- Müller, J., Lips, K.S., Metzger, L., Neubert, R.H.H., Koepsell, H., and Brandsch, M. 2005. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). *Biochem. Pharmacol.* 70: 1851-1860.
- Mushiroda T., Douya R., Takahara E., and Nagata O. 2000. The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. *Drug Metab. Dispos.* 28(10): 1231-1237.

- Negróni, R., Robles, A.M., Arechavala, A., *et al.* 1980. Ketoconazole in the treatment of paracoccidioidomycosis and histoplasmosis. *Rev. Infect. Dis.* 2: 643-649.
- Neubaure, M.A., and Bodensteiner, D.C. 1982. Disseminated histoplasmosis in patients with AIDS. *South. Med. J.* 85: 1166-1170.
- Neuvonen, P.J., and Suhonen, R. 1995. Itraconazole interact with felodipine. *J. Am. Acad. Dermatol.* 33: 134-135.
- Niemi, M., Backman, J.T., Neuvonen, M., and Neuvonen, P.J. 2003. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. *Br. J. Clin. Pharmacol.* 56: 427-432.
- Niemi, M., Backman, J.T., Neuvonen, M., Neuvonen, P.J., and Kivisto, K.T. 2000. Rifampicin decreases the plasma concentrations and effects of repaglinide. *Clin Pharmacol Ther.* 68: 495-500.
- Niemi, M., Backman, J.T., Neuvonen, M., Neuvonen, P.J., and Kivisto, K.T. 2001. Effects of rifampicin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. *Clin. Pharmacol. Ther.* 69: 400-406.
- Niemi M, Backman JT, Neuvonen PJ (2004). Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. *Clin. Pharmacol. Ther.* 76(3): 239-249.
- Niemi, M., Backman, J.T., Neuvonen, P.J. 2004. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. *Clin. Pharmacol. Ther.* 76(3): 239-49.

- Njenga, S., Mitsui, Y., Muita, M., Fujimaki, Y., Mbugua, J., Kirigi, G., Gachihi, G., Wasunna, M., and Aoki, Y. 1997. The effect of sodium bicarbonate on a single dose of diethylcarbamazine therapy in patients with bancroftian filariasis in Kenya. *Parasitology International*. 46: 171-179.
- O' Reilly, R.A. 1974. Interaction of sodium warfarin and rifampicin. *Ann. Intern. Med.* 81: 337-340.
- O'Reilly, R.A. 1975. Interaction of chronic daily warfarin therapy and rifampin. *Ann Intern Med.* 83(4):506-8.
- Oftebro, H., Jensen, J., Mowinchel, P., *et al.* 1994. Establishing a ketoconazole suppression test for verifying testosterone administration in the doping control of athletes. *J. Clin. Endocrinol. Metab.* 78(4): 973-977.
- Olkkola, K.T., Backman, J.T., Neuvonen, P.J. 1994. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. *Clin. Pharmacol. Ther.* 55(5): 481-5.
- Ottensen, E.A., and Ramachandran, C.P. 1995. Lymphatic filariasis infection and disease: *Parasitol. Today*. 11: 129-131.
- Pappas, P.G., Pottage, J.C., Powderly, W.G., *et al.* 1992. Blastomycosis in patients with the acquired immunodeficiency syndrome. *Ann. Intern. Med.* 116: 847-853.
- Park, J.Y., Kin, K.A., Park, P.W., Park, C.W., and Shin, J.G. 2003. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. *Clin. Pharmacol. Ther.* 74(4): 334-340.

- Park, J.Y., Kin, K.A., Kang, M.H., Kin, S.L., and Shin, J.G. 2004. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. *Clin. Pharmacol. Ther.* 75 (3): 157-162.
- Park, J.Y., Kin, K.A., Shin, J.G., and Lee, K.Y. 2004. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. *Br. J. Clin. Pharmacol.* 58(4): 397-402.
- Parkinson, A. 1996. Casarett & Doull's : Toxicology, The basic science of poisons (5th ed.) international edition. *McGraw Hill*, New York; 134-139.
- Pedersen, K.E. 1985. Digoxin interaction: the influence of quinidine and verapamil on pharmacokinetics and receptor binding of digitalis glycosides. *Acta Med. Scand.* 697 (suppl.): 11-40.
- Pershing, L.K., Corlett, J., and Jorgensen, C. 1994. *In vivo* pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human skin. *Antimicrob. Agents Chemother.* 38(1): 90-95.
- Piscitelli, S.C., Goss, T.F., Wilton, J.H., D'Andrea, D.T., Goldstein, H., Schentag, J.J. 1991. Effects of ranitidine and sucralfate on ketoconazole bioavailability. *Antimicrob. Agents Chemother.* 35(9):1765-71.
- Polk, R.E., Brophy, D.F., Israel, D.S., Patron, R., Sadler, B.M., Chittick, G.E., Symonds, W.T., Lou, Y., Kristoff, D., and Stein, D.S. 2001. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. *Antimicrob. Agents Chemother.* 45(2): 502-508.
- Polk, R.E., Crouch, M.A., Israel, D.S., *et al.* 1999. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. *Pharmacotherapy.* 19: 1378-1384.

Prober, C.G. 1985. Effect of rifampicin on chloramphenicol levels. *N. Engl. J. Med.* 312: 788-789.

Product Information. 1999. Abelcet[®], amphotericin B lipid complex. The Liposome Company, Inc., Princeton, NJ.

Product Information. 1995. Nizoral[®] 2% Shampoo. Janssen Pharmaceutica, Titusville, NJ.

Product Information. 1996. Nizoral[®], ketoconazole. Janssen Pharmaceutica, Titusville, NJ.

Product Information. 1998. Nizoral[®], ketoconazole. Janssen Pharmaceutica, Titusville, NJ.

Product Information. 2000. Nizoral[®] 2% Shampoo. Janssen Pharmaceutica, Titusville, NJ. (PI revised 7/1998) reviewed 2000.

Product Information. 1997. versed[®], midazolam. Roche Laboratories Inc., Titusville, NJ.

Product Information. 1996. Xanax[®], alprazolam. Pharmacia & Upjohn Company, Kalamazoo, MI.

Renton, K.W. 1986. Factors affecting drug biotransformation. *Clin. Biochem.* 19: 72-75.

Restrepo, A., Stevens, D.A., Gomez, I., *et al.* 1980. Ketoconazole: a new drug for the treatment of paracoccidioidomycosis. *Rev. Infect. Dis.* 2: 633-642.

Reynolds, J.E.F., Parfitt, K., Parsons, A.V., and Sweetman, S.C. 1993. *Martindale The Extra Pharmacopoeia* (30th ed.), London: The Pharmaceutical Press. pp. 41.

- Ribera, E., Pou, L., Fernandez-Sola, A., Campos, F., Lopez, R.M., Ocana, I., Ruiz, I., and Pahissa, A. 2001. Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients. *Antimicrob. Agents Chemother.* 45(11): 3238-3241.
- Ridtitid, W., Wongnawa, M., Mahathanatrakul, W., Chaipol, P., and Sunbhanich, M. 2000. Effect of rifampicin on plasma concentrations of mefloquine in healthy volunteers. *J. Pharm. Pharmacol.* 52: 1265-1269.
- Ridtitid, W., Wongnawa, M., Mahathanatrakul, W., Punyo, J., and Sunbhanich, M. 2002. LC determination of praziquantel in human plasma. *J. Pharm. Biomed. Anal.* 28: 181-186.
- Robertson, M.H., Hanifin, J.M., and Parker, F. 1980. Oral therapy with ketoconazole for dermatophyte infections unresponsive to griseofuvin. *Rev. Infect. Dis.* 2: 578-581.
- Rosenthal, P., and Goldsmith, R.S. 1998. A LANGE medical book: Basic & Clinical pharmacology (9th ed., vol. 2). *McGraw-Hill*, Boston. pp. 889.
- Rowland, M., and Tozer, T.N. 1995. Clinical Pharmacokinetics in griseofuvin resistant dermatophytosis. *J. Am. Acad. Dermatol.* 6: 224-229.
- Saadeddin, A., Torres-Molina, F., Cárcel-Trullols, J., Araico, A., and Peris, J.E. 2004. Effect of cytochrome P450 inhibitors (diethyl dithiocarbamate, ketoconazole and grapefruit juice) on the pharmacokinetics of all-*trans*-retinoic acid. *IL FARMACO.* 59: 697-702.

- Saima, S., Furuie, K., Yoshimoto, H., Fukuda, J., Hayashi, T., and Echizen, H. 2002. The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. *Br. J. Clin. Pharmacol.* 53: 203-206.
- Seidegård J. 2000. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration. *Clin. Pharm. Ther.* 68(1): 13-17.
- Self, T.H., and Morris, T. 1980. Interaction of rifampicin and chlorpropamide. *Chest.* 77: 800-801.
- Serody, J.S., Mill, M.R., Detterbeck, F.C., *et al.* 1993. Blastomycosis in transplant recipients: report of case and review. *Clin. Infect. Dis.* 16: 54-58.
- Shenoy, R.K., Suma, T.K., John, A., Arun, S.R., Kumaraswami, V., Fleckenstein, L.L., and Nangchang, K. 2000 The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole. *Ann. Trop. Med. Parasitol.* 96(6): 603-614.
- Shuster, S. 1984. The etiology of dandruff and mode of action of therapeutic agents. *Br. J. Dermatol.* 111: 235-242.
- Siegler, D.I., Bryant, M., Burley, D.M., Citron, K.M., and Standen, S.M. 1974. Effect of meals on rifampicin absorption. *Lancet.* 27: 197-198.
- Silverman, J.A. 2000. P-glycoprotein. In R.H. Levy, *Metabolic Drug Interactions*. Philadelphia: A Wolters Kluwer. pp. 135-144.
- de Silva, N., Guyatt, H., and Bundy, D. 1997. Anthelmintics, A comparative review of their clinical pharmacology. *Drugs.* 53: 769-788.

- Silverira, L.H., Cuellar, M.L., Citera, G., *et al.* 1993. Candida arthritis. *Rheum. Dis. Clin. North Am.* 19: 427-437.
- Smith, A.G. 1984. Potentiation of oral anticoagulants by ketoconazole. *Br. Med. J.* 288: 188-189.
- Snook, J., Boothman, B.D., Watkins, J., *et al.* 1988. Torsade de point ventricular tachycardia associated with astemizole overdose. *Br. J. Clin. Pract.* 42: 257-259.
- Sobel, J.D. 1986. Recurrent vulvovaginal candidiasis: a prospective study of the efficacy of maintenance ketoconazole therapy. *N. Engl. J. Med.* 315: 1455-1458.
- Spahn-Langguth, H., Baktir, G., Radschuweit, A., Okyar, A., Terhaag, B., Ader, P., Hanafy, A., and Langguth, P. 1998. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential *in vivo* relevance of *in vitro* data employing talinolol as model compound. *Int. J. Clin. Pharmacol. Ther.* 36: 16-24.
- Spiro, R.C., Parsons, W.G., Perry, S.K., Caulfield, J.P., Hein, A., Reisfeld, R.A., Harper, J.R., Austen, K.F., and Stevens, R.L. 1986. Inhibition of post-translational modification and surface expression of a melanoma-associated chondroitin sulfate proteoglycan by diethylcarbamazine or ammonium chloride. *J. Biol. Chem.* 261: 5121-5129.
- Stone, J.A., Migoya, E.M., Hickey, L., Winchell, G.A., Deutsch, P.J., Ghosh, K., Freeman, A., Bi, S., Desai, R., Dilzer, S.C., Lasseter, K.C., Kraft, W.K., Greenberg, H., and Waldman, S.A. 2004. Potential for interactions between caspofungin and nelfinavir or rifampin. *Antimicrob. Agents Chemother.* 48(11): 4306-4314.
- Strayhorn, V.A., Bacicwicz, A.M., and Self, T.H. 1997. Update on rifampicin drug interaction III. *Arch. Intern. Med.* 157: 2453-2458.

- Sugar, A.M., Alsip, S.G., Galgiani, J.N., *et al.* 1987. Pharmacology and toxicity of high dose of ketoconazole. *Antimicrob. Agents Chemother.* 31: 1874-1878.
- Suzuki, S., Kurata, N., Nishimura, Y., Yasuhara, H., Satoh, T. 2000. Effects of imidazole antimycotics on the liver microsomal cytochrom P450 isoforms in rats: comparison of *in-vitro* and *ex-vivo* studies. *Eur J Drug Metab. Pharmacokinet.* 25: 21-126.
- Swartz, M., and Krull, I.S. 1997. Method development, optimization, and validation approaches. Analytical method development and validation. p. 53-72; New York: Marcel Dekker.
- Sweet, D.H. 2005. Organic anion transporter (Slc22a) family members as mediators of toxicity. *Toxicol. App. Pharmacol.* 204: 198-215.
- Syvalahti, E.K.G., Pihlajamaki, K.K., and Lisalo, E.J. 1974. Rifampicin and drug metabolism. *Lancet.* 2: 232-233.
- Syvalahti, E.K.G., Pihlajamaki, K.K., and Lisalo, E.J. 1975. Effect of tuberculostatic agents on the response of serum growth hormone and immunoreactive insulin to intravenous tolbutamide and on the half-life of tolbutamide. *Intern. J. Clin. Pharmacol. Toxicol. Ther.* 13: 83-89.
- Taylor, S., Gupta, A., Walker, S., *et al.* 1996. Peripheral edema due to nifedipine-itraconazole interaction: a case report. *Arch. Dermatol.* 132: 350-352.
- Talbot, M.D., and Spencer, R.C. 1983. Oral ketoconazole in the treatment of vaginal candidiasis. *Cur. Ther. Res.* 34: 746-749.

- Tamai, I., Ohashi, R., Nezu, J., *et al.* 1998. Molecular and functional identified cation of sodium ion-dependent, high affinity human carnitine transporter OCTN2. *J. Biol. Chem.* 273: 20378-20382.
- Tamai, I., Yabuuchi, H., Nezu, J., *et al.* 1997. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. *FEBS Lett.* 419: 107-111.
- Terhell, A.J., Haarbrink, M., Van Den Biggelaar, A., Mangali, A., Sartono, E., and Yazdanbakhsh, M. 2003. Long-term Follow-up of treatment with diethylcarbamazine on anti-filarial IgG4: Dosage, compliance, and differential patterns in adults and children. *Am. J. Trop. Med. Hyg.* 68: 33-39.
- Tracy, J.W., and Webster Jr., L.T. 2001. Drug Used in the Chemtherapy of Helminthiasis. Goodman & Gilman's: The pharmacological Basis of Therapeutics (10th ed.); p.1129-1130. New York: *McGraw-Hill*.
- Tsunoda, S.M., Velez, R.L., von Moltke, L.L., Greenblatt, D.J. 1999. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of imidazolam as in-vivo probe: effect of ketoconazole. *Clin. Pharmacol. Ther.* 66: 461-471.
- Van Der Meer, J.W.M., Kening, J.J., Scheijrond, H.W., Heykants, J., Van Cutsem, J., *et al.* 1980. Influence of gastric acidity on the bioavailability of ketoconazole. *J. Antimicrob. Chemother.* 6: 522-524.
- Van tyle, J.H. 1984. Ketoconazole, mechanism of action spectrum of activity pharmacokinetics, drug interaction, adverse reaction and therapeutic use. *Pharmacotherapy.* 4: 343-373.
- Varhe, A., Olkkola, K.T., Neuvonen, P.J. 1994. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. *Clin. Pharmacol. Ther.* 56: 601-607.

- Venkatakrishnan, K., von Moltke, L.L., Greenblatt, D.J. 2000. Effects of the antifungal agents on oxidative drug metabolism. *Pharmacokinetic*. 38(2): 111-180.
- Venkatesan, K. 1992. Pharmacokinetic drug interactions with rifampicin. *Clin. Pharmacokinetic*. 22: 47-65.
- Verschraagen, M., Koks, C.H.W., Schellens, J.H.M., and Beijnen, J.H. 1999. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. *Pharmacol. Res.* 40: 301-306.
- Vidal-Puig, A.J., Munoz-Torres, M., Jodar-Gimeno, E., *et al.* 1994. Ketoconazole therapy: hormonal and clinical effect in non-tumoral hyperandrogenism. *Eur. J. Endocrinol.* 130: 333-338.
- Villikka, K., Kivisto, K.T., Backman, J.T., Olkkola, K.T., and Neuvonen, P.J. 1997. Triazolam is ineffective in patients taking rifampicin. *Clin. Pharmacol. Ther.* 61: 8-14.
- Villikka, K., Kivisto, K.T., Luurila, H., and Neuvonen, P.J. 1997. Rifampicin reduces plasma concentrations and effects of zolpidem. *Clin. Pharmacol. Ther.* 62: 629-634.
- Villikka, K., Kivisto, K.T., Neuvonen, P.J. 1999. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. *Clin Pharmacol Ther.* 65(4): 377-81.
- Wandel, C., Kim, R.B., Kajiji, S., Guenerich, F.P., Wilkinson, G.R., and Wook, A.J.J. 1999. P-glycoprotein and cytochrome P450 3A inhibition: dissociation of inhibitory potencies. *Cancer Res.* 59: 3944-3948.
- Wanwimolruk, S., Wong, S.M., Z nang, H., Coville, P.F., and Walker, R.J. 1995. Metabolism of quinine in man : identification of a major metabolite, and effects of smoking and rifampicin pretreatment. *J. Pharm. Pharmacol.* 47: 955-963

- Welsh, O., and Rodriguez, M. 1980. Treatment of dermatomycosis with ketoconazole. *Rev. Infect. Dis.* 2: 582-585.
- Westphal, K., Weinbrenner, A., Zschiesche, M., Oertel, R., Terhaag, B., Kroemer, H., and Siegmund, W. 2000. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. *Clin. Pharmacol. Ther.* 68: 345-355.
- WHO, 1998. Tuberculosis fact sheet. *Global Tuberculosis Programme*.
- WHO, 2000. Lymphatic filariasis fact sheet.
- William, A., and Petri, Jr. 2001. Antimicrobial Agents: In J.G. Hardman and L.E. Limbird (eds), *Goodman and Gilman's the pharmacological Basis of Therapeutics* (10th ed.). New York: McGraw-Hill. pp. 1273-1294.
- Windholz, M., Budavari, S., Stroumtsos, L.Y., and Fertig, M.N. 1976. *The Merck Index*. (9th ed.), 1068 pp. U.S.A.: Merck & Co., Inc.
- Winqvist, E.W., Laskey, J., Crump, M., *et al.* 1995. Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production. *J. Clin. Oncol.* 13: 157-164.
- Wright, S.H. 2005. Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. *Toxicol. App. Pharmacol.* 204: 309-319.
- Wright, S.H., and Dantzler, W.H. 2004. Molecular and cellular physiology of renal organic cation and anion transport. *Physiol. Rev.* 84: 987-1049.
- Zhou, H.H., Feng, H.J., Huang, S.L., and Wang, W. 1997. Inducing effect of rifampin on CYP2C19 is related to gene dose. *Clin. Pharmacol. Ther.* 61:277.